Dr Reddys Laboratories (RDY) Cash from Financing Activities (2024 - 2025)

Dr Reddys Laboratories (RDY) recorded quarterly Cash from Financing Activities of -$61.0 million in Q3 2025, down 334.15% quarter-over-quarter from -$14.1 million in Q2 2025, and down 131.65% on a YoY basis from $192.8 million in Q3 2024.

Dr Reddys Laboratories (RDY) Cash from Financing Activities (2024 - 2025) Analysis & Trends

Dr Reddys Laboratories' Cash from Financing Activities history runs 2 years deep, the most recent figure standing at -$61.0 million for Q3 2025.

  • In Q3 2025, Cash from Financing Activities fell 131.65% year-over-year to -$61.0 million; the TTM figure through Sep 2025 stood at $232.1 million (changed N/A YoY), while the FY2026 annual figure was $88.0 million, down 60.36% from the prior year.
  • Cash from Financing Activities was -$61.0 million for Q3 2025 at Dr Reddys Laboratories, down from -$14.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $192.8 million in Q3 2024 to a low of -$61.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 13.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -840.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -1.48 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -86.10 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -65.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 1.47 Bn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -77.88 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn -11.62 Mn
10 Dr Reddys Laboratories 122.03 Mn -51.98 Mn 368.55 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 -61.03 Mn
Sep 30, 2025 -61.03 Mn
Jun 30, 2025 -14.06 Mn
Jun 30, 2025 -14.06 Mn
Sep 30, 2024 192.82 Mn
Sep 30, 2024 192.82 Mn
Jun 30, 2024 114.37 Mn
Jun 30, 2024 114.37 Mn